For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| License and development support revenue (including related party amounts of 0 and 251, respectively) | - | 0 | - | - |
| Research and development (including related party amounts of 13 and 23, respectively) | 19,312 | 16,994 | 17,633 | 17,861 |
| General and administrative | 5,118 | 4,938 | 5,264 | 4,949 |
| Total operating expenses | 24,430 | 21,932 | 22,897 | 22,810 |
| Loss from operations | -24,430 | -21,932 | -22,897 | -22,810 |
| Interest income | 912 | 1,162 | 1,372 | 1,561 |
| Change in fair value of safes (including related party amounts of 0 and 2,911, respectively) | - | 0 | - | - |
| Other income (expense), net | 2 | -2 | -3 | -5 |
| Total other income , net | 914 | 1,160 | 1,369 | 1,556 |
| Net loss | -23,516 | -20,772 | -21,528 | -21,254 |
| Unrealized gain (loss) on investments, net | - | - | - | 2 |
| Unrealized (gain) loss on investments, net | -121 | 16 | 85 | - |
| Comprehensive loss | -23,637 | -20,756 | -21,443 | -21,252 |
| Basic EPS | -0.95 | -0.845 | -0.88 | -0.87 |
| Diluted EPS | -0.95 | -0.845 | -0.88 | -0.87 |
| Basic Average Shares | 24,678,420 | 24,573,705 | 24,481,722 | 24,378,823 |
| Diluted Average Shares | 24,678,420 | 24,573,705 | 24,481,722 | 24,378,823 |
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. (ARTV)